These ASX 200 shares could rise 30% to 40%

Let's see what analysts are saying about these buy-rated shares.

| More on:
Person pointing finger on on an increasing graph which represents a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you are on the hunt for big returns for your investment portfolio, then keep reading.

That's because listed below are two ASX 200 shares that have been named as buys and tipped to rise over 30% from current levels.

Here's why brokers are bullish on these big names:

Mineral Resources Ltd (ASX: MIN)

Bell Potter thinks that this mining and mining services company's shares are dirt cheap despite a strong rebound this week.

In response to Mineral Resources' quarterly update, the broker has reaffirmed its buy rating on the ASX 200 share with an improved price target of $29.50. Based on its current share price of $20.50, this implies potential upside of 44% for investors over the next 12 months.

Commenting on its buy recommendation, the broker said:

We maintain our Buy recommendation on valuation grounds. We continue to hold the view that (1) Onslow will be commissioned successfully, (2) associated Iron Ore & Services volumes will enable deleveraging of the balance sheet, (3) MIN has other options to manage its debt, including re-financing, and further asset sell downs, and (4) MIN's deleveraging will co-inside with it addressing its leadership and governance issues. Our Target Price is most sensitive to iron ore price. Long-term we apply US$95/t (62% CIF) vs the current spot of ~US$99/t. We share the view that iron ore will continue to see support in the US$80/t – US$100/t range.

ResMed Inc. (ASX: RMD)

Analysts at Goldman Sachs continue to believe that this sleep disorder treatment company's shares are being undervalued by the market.

The broker was pleased with ResMed's performance during the third quarter and particularly its gross margin improvement.

In response, Goldman reiterated its conviction buy rating on the ASX 200 share with an improved price target of $49.30. Based on its current share price of $36.77, this suggests that upside of 34% is possible for investors over the next 12 months.

Its analysts are bullish due to ResMed's strong growth outlook and the "unjustified" low multiples its shares trade on. It said:

RMD is the world's leading CPAP manufacturer of devices and masks in the treatment of OSA. The company has expanded to providing software services to out of hospital healthcare providers including Durable Equipment Manufacturers (DMEs), nursing homes and home health and hospice agencies. Our Buy recommendation on RMD is premised on (1) Ongoing robust new patient growth for CPAP therapy despite the market entry of GLP-1 drugs to treat OSA, (2) Further RMD market share gains, building on its #1 global market position, (3) Expansion of the OSA market in regions outside of the US. We believe the stock's current trading multiple is unjustified based on its growth outlook.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Two lab workers fist pump each other.
Broker Notes

What's JP Morgan's price target on CSL shares?

Are CSL shares undervalued or will they continue to underperform?

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Macquarie tips 33% return for this ASX 200 stock

The broker thinks this blue chip could be cheap at current levels.

Read more »

A woman in her late 30s holds her hands out either side with the palms up as if indicating she doesn't know the answer to a question. She has a quizzical look on her face.
Broker Notes

The A2 Milk share price: Buy, hold, sell?

Let's see what Bell Potter is saying about this popular stock.

Read more »

A smiling woman holds a Facebook like sign above her head.
Broker Notes

Morgans names 2 top ASX shares to buy now

What is the broker recommending to clients this week?

Read more »

It's raining cash for this man, as he throws money into the air with a big smile on his face.
Broker Notes

2 of the best ASX 200 shares that money can buy

Let's see why Bell Potter thinks these are among the best shares to buy now.

Read more »

Young fruit picker clipping bunch of grapes in vineyard.
Broker Notes

How much upside does Macquarie see for Treasury Wine shares?

Macquarie has a neutral view on Treasury Wine shares, with an $8.50 price target and 11% upside.

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

Why this top ASX 200 stock could deliver a 20%+ return

Bell Potter has good things to say about this growing company.

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »